How to access Besremi from Qatar, the named-patient import pathway, 2026

By Reserve Meds, Clinical and regulatory team. Last reviewed 2026-05-13.

A Qatari patient with polycythemia vera (PV) may receive a prescription for Besremi (ropeginterferon alfa-2b-njft) from their treating hematologist. Besremi is FDA-approved in the United States and manufactured by PharmaEssentia. It is a long-acting monopegylated interferon alfa-2b administered by subcutaneous injection every two weeks during initiation and titration, and every four weeks during maintenance once hematologic response is achieved. Local availability of Besremi in Qatar can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or supply may be back-ordered. When that happens, a named-patient import pathway through MoPH remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Besremi is a long-acting monopegylated interferon alfa-2b. Mechanism: a recombinant interferon alfa-2b with a 40-kDa monomethoxy polyethylene glycol moiety conjugated at a single proline residue, designed to deliver sustained interferon receptor stimulation with biweekly to monthly dosing. Dosing: titration from 100 mcg subcutaneously every two weeks, increasing by 50 mcg every two weeks to a maximum of 500 mcg, then transitioning to every-four-week dosing once hematologic response is achieved, per FDA labeling. Baseline workup per FDA labeling includes CBC with differential, hematocrit, comprehensive metabolic panel, thyroid function, lipid panel, ophthalmologic assessment, and psychiatric history review. Other important warnings include depression, suicidal ideation and behavior, endocrine disorders including thyroid dysfunction and diabetes, cardiovascular disorders, autoimmune disorders, ophthalmologic disorders, pulmonary toxicity, hepatotoxicity, and pancreatitis. The FDA labeling carries a boxed warning for risk of serious depression and other neuropsychiatric symptoms. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Is Besremi legally importable into Qatar?

Yes, through the Qatar Ministry of Public Health (MoPH) named-patient and personal-use import framework, coordinated through a Qatari-licensed treating facility's pharmacy. Qatar has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The MoPH named-patient route allows a Qatari-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

  1. Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the PV diagnosis, prior cytoreductive therapy where relevant, and rationale for Besremi.
  2. Baseline screening. CBC with differential, hematocrit, comprehensive metabolic panel, thyroid function, lipid panel, ophthalmologic assessment, and psychiatric history review are confirmed and documented.
  3. MoPH named-patient application. Your hematologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
  4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from PharmaEssentia's authorised distribution under DSCSA chain-of-custody.
  5. Cold-chain shipment. Besremi requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
  6. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy on the titration schedule.

What documentation your physician needs

Your physician will typically need to provide:

  • A clinical rationale letter confirming the polycythemia vera diagnosis (including JAK2 V617F status where relevant), prior cytoreductive therapy where relevant, and Besremi as the indicated next step
  • Verification of their Qatari medical licence
  • A patient identifier, anonymised reference where privacy is preferred
  • Documented pre-treatment screening consistent with FDA labeling (see above), including psychiatric history and ophthalmologic baseline
  • The planned titration regimen (start at 100 mcg, increase by 50 mcg every two weeks to maximum 500 mcg, per FDA labeling)
  • A monitoring plan covering CBC, hematocrit target, thyroid function, depression screening at each visit, and ophthalmologic and pulmonary surveillance

Reserve Meds provides a physician documentation kit tailored for long-acting interferon therapies, including the templates MoPH reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a typical month of Besremi at maintenance dosing sits in an indicative 2026 band of approximately USD 10,000 to 14,000. International logistics, MoPH documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 3 to 6 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort. All timelines are indicative, not guarantees.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Besremi specifically, we provide:

  • Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
  • Documentation. Regulatory package tailored for your physician and for MoPH review, including pegylated interferon class templates.
  • Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
  • Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed Qatari pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Qatar? Yes, when executed through the MoPH named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Qatari tertiary centers.

Will my private health insurance cover this? Cash-pay is the default posture. Some Qatari private insurance plans review named-patient imports case-by-case on a pre-authorisation basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.

How does Besremi differ from hydroxyurea? Hydroxyurea is a cytoreductive oral chemotherapy commonly used in PV; Besremi is a long-acting interferon that targets the clonal JAK2-mutated stem cell population. Choice between them is a clinical decision your hematologist will make based on age, prior therapy, family planning, and tolerability. Besremi labeling specifically notes use in adults with PV regardless of prior cytoreductive treatment history.

How does cold-chain affect timing? Besremi ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Qatari tertiary centers (Hamad Medical Corporation, Sidra Medicine, and Al Ahli Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoPH reviewers commonly ask for.

Join the waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Besremi coordination in Qatar.

Add me to the Besremi waitlist

Composite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice. Reserved for you.